Published in Vaccine Weekly, September 27th, 1999
The first grant is a six-month Phase I award of approximately $100,000 for preliminary development of a sensitive and specific polymerase chain reaction (PCR) assay for Babesia DNA to be used in both the early diagnosis of babesiosis and in the monitoring of therapy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.